CRISPR Therapeutics AG (CRSP) Change in Acquisitions & Divestments (2020 - 2026)

CRISPR Therapeutics AG has disclosed Change in Acquisitions & Divestments across 7 years of filings, most recently posting -$8.5 million for Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 104.03% year-over-year to -$8.5 million; the TTM figure through Jun 2026 stood at $798.4 million (down 21.56% YoY), while the FY2025 annual figure was $1.0 billion, down 16.27% from the prior year.
• Change in Acquisitions & Divestments came in at -$8.5 million for Q2 2026 at CRISPR Therapeutics AG, down from $192.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $419.7 million in Q3 2022 to a low of -$8.5 million in Q2 2026.
• Average Change in Acquisitions & Divestments over 5 years is $280.7 million, with a median of $293.7 million recorded in 2023.
• Year-over-year, Change in Acquisitions & Divestments surged 194.21% in 2022 and sank 104.03% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $325.1 million in 2022, then fell by 11.57% to $287.4 million in 2023, then grew by 29.77% to $373.0 million in 2024, then decreased by 19.58% to $300.0 million in 2025, then tumbled by 102.84% to -$8.5 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were -$8.5 million in Q2 2026, $192.8 million in Q1 2026, and $300.0 million in Q4 2025.